Trial Profile
A Prospective, Open-Labelled, Non-Controlled, Observational Study to Assess the Efficacy and Safety of NovoRapid™ FlexPen™ in the Treatment of Acute Hyperglycemia: A Post-Marketing Surveillance Study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2016
Price :
$35
*
At a glance
- Drugs Insulin aspart (Primary)
- Indications Hyperglycaemia
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 24 May 2012 Official title amended as reported by ClinicalTrials.gov.
- 09 Oct 2009 Actual patient number (373) added as reported by ClinicalTrials.gov.
- 02 Jun 2008 New trial record.